Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Camilla Fuchs Andersen

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Cardiovascular Diabetology|January 29, 2026
Associations of body mass index on worsening of heart failure and mortality in patients with heart failure and reduced left ventricular ejection fraction: a 10-year follow-up study (a NorthStar substudy)Morten Malmborg, Mohamed El-Chouli, Camilla Fuchs Andersen, et al.
The Lancet Regional Health. Europe|November 20, 2025
Care and outcomes of first-time myocardial infarction among vulnerable populations in Denmark, 2003-22: a nationwide registry-based cohort studyClara Friis, Sofie-Louise Feentved Ødum, Caroline Hartwell Garred, et al.
Journal of the American Heart Association|April 9, 2026
Care and Outcomes of New-Onset Heart Failure Across Vulnerable Populations: Temporal Trends in Mortality and Treatment in a Danish Nationwide Cohort From 2003 to 2022Sofie-Louise Feentved Ødum, Clara Friis, Caroline Hartwell Garred, et al.
Journal of Cardiac Failure|March 14, 2026
The effect of empagliflozin on left ventricular mass and volumes in elderly individuals with overweight and high risk of heart failure: The Empire Prevent Cardiac TrialJulie Hempel Larsen, Camilla Fuchs Andersen, Maria Callesen Hansen, et al.
European Journal of Preventive Cardiology|January 8, 2026
Effects of empagliflozin in patients at risk of heart failure: the Empire Prevent Metabolic TrialCamilla Fuchs Andersen, Julie Hempel Larsen, Massar Omar, et al.
Cardiovascular Diabetology|June 13, 2026
The effect of empagliflozin on inflammation in patients with overweight or obesity and risk of heart failure: a substudy from the Empire Prevent Metabolic trialCamilla Fuchs Andersen, Julie Hempel Larsen, Massar Omar, et al.
Journal of the American Heart Association|February 3, 2025
Temporal Trends in Mortality and Hospitalization Risk in Patients With Heart Failure According to the Hospital Frailty Risk ScoreNoor K Abassi, Nina Nouhravesh, Mariam Elmegaard, et al.
European Journal of Heart Failure|November 15, 2022
Effects of empagliflozin on erythropoiesis in heart failure: data from the Empire HF trialCamilla Fuchs Andersen, Massar Omar, Andreas Glenthøj, et al.
Cardiovascular Diabetology|August 2, 2025
Erythrocytosis incidence and thromboembolic risk in heart failure with reduced ejection fraction treated with SGLT2 inhibitors: a nationwide register-based cohort studyAbdullahi Ahmed Mohamed, Camilla Fuchs Andersen, Daniel Mølager Christensen, et al.
American Heart Journal|February 16, 2024
Empagliflozin to elderly and obese patients with increased risk of developing heart failure: Study protocol for the Empire Prevent trial programCamilla Fuchs Andersen, Julie Hempel Larsen, Jesper Jensen, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Cardiovascular Diabetology|January 29, 2026
Associations of body mass index on worsening of heart failure and mortality in patients with heart failure and reduced left ventricular ejection fraction: a 10-year follow-up study (a NorthStar substudy)Morten Malmborg, Mohamed El-Chouli, Camilla Fuchs Andersen, et al.
The Lancet Regional Health. Europe|November 20, 2025
Care and outcomes of first-time myocardial infarction among vulnerable populations in Denmark, 2003-22: a nationwide registry-based cohort studyClara Friis, Sofie-Louise Feentved Ødum, Caroline Hartwell Garred, et al.
Journal of the American Heart Association|April 9, 2026
Care and Outcomes of New-Onset Heart Failure Across Vulnerable Populations: Temporal Trends in Mortality and Treatment in a Danish Nationwide Cohort From 2003 to 2022Sofie-Louise Feentved Ødum, Clara Friis, Caroline Hartwell Garred, et al.
Journal of Cardiac Failure|March 14, 2026
The effect of empagliflozin on left ventricular mass and volumes in elderly individuals with overweight and high risk of heart failure: The Empire Prevent Cardiac TrialJulie Hempel Larsen, Camilla Fuchs Andersen, Maria Callesen Hansen, et al.
European Journal of Preventive Cardiology|January 8, 2026
Effects of empagliflozin in patients at risk of heart failure: the Empire Prevent Metabolic TrialCamilla Fuchs Andersen, Julie Hempel Larsen, Massar Omar, et al.
Cardiovascular Diabetology|June 13, 2026
The effect of empagliflozin on inflammation in patients with overweight or obesity and risk of heart failure: a substudy from the Empire Prevent Metabolic trialCamilla Fuchs Andersen, Julie Hempel Larsen, Massar Omar, et al.
Journal of the American Heart Association|February 3, 2025
Temporal Trends in Mortality and Hospitalization Risk in Patients With Heart Failure According to the Hospital Frailty Risk ScoreNoor K Abassi, Nina Nouhravesh, Mariam Elmegaard, et al.
European Journal of Heart Failure|November 15, 2022
Effects of empagliflozin on erythropoiesis in heart failure: data from the Empire HF trialCamilla Fuchs Andersen, Massar Omar, Andreas Glenthøj, et al.
Cardiovascular Diabetology|August 2, 2025
Erythrocytosis incidence and thromboembolic risk in heart failure with reduced ejection fraction treated with SGLT2 inhibitors: a nationwide register-based cohort studyAbdullahi Ahmed Mohamed, Camilla Fuchs Andersen, Daniel Mølager Christensen, et al.
American Heart Journal|February 16, 2024
Empagliflozin to elderly and obese patients with increased risk of developing heart failure: Study protocol for the Empire Prevent trial programCamilla Fuchs Andersen, Julie Hempel Larsen, Jesper Jensen, et al.
Pageof 2